Philippines in Talks With Pfizer, Sinovac for Covid-19 Vaccines
(Bloomberg) --
The Philippines will meet with representatives of Pfizer Inc. and the Russian Embassy on Friday as it seeks to source Covid-19 vaccines to combat Southeast Asia's worst outbreak.
The government is also in talks with counterparts in Indonesia and China for possible clinical trials and for vaccine supplies from Sinovac Biotech Co. Ltd., Health Undersecretary Maria Rosario Vergeire said at a virtual briefing on Friday. The Chinese drugmaker, which will supply 50 million doses to Indonesia, could partner with Manila-based IP Biotech Inc. to set up a local packaging and distribution facility for the vaccine, she said.
Southeast Asia's Virus Hotspot Risks Losing in Vaccine Race (1)
Phase 3 trials for Russia's Sputnik V vaccine are still under review though they were targeted to start by October, Vergeire said. Budget and approval delays have pushed back trials for the Japanese antiviral drug Avigan as treatment for Covid-19 to this month from mid-August, she said.
The Philippines reported 3,714 new infections on Friday, bringing the total to more than 230,000 cases.
©2020 Bloomberg L.P.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.